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Clusterin (CLU) is an extracellular chaperone 
that is likely to play an important role in 
protein folding quality control. This study 
identified three deposition disease-associated 
proteins as major plasma clients for clusterin 
by studying CLU-client complexes formed in 
response to physiologically relevant stress 
(shear stress ~ 36 dye/cm2 at 37oC).  Analysis of 
plasma samples by size exclusion 
chromatography (SEC) indicated that (i) 
relative to control plasma, stressed plasma 
contained proportionally more soluble protein 
species of high molecular weight (HMW), and 
(ii) HMW species were far more abundant 
when proteins purified by anti-CLU 
immunoaffinity chromatography from stressed 
plasma were compared to those purified from 
control plasma. SDS-PAGE and Western blot 
analyses indicated that a variety of proteins co-
purified with CLU from both stressed and 
control plasma, however, several proteins were 
uniquely present or much more abundant 
when plasma was stressed. These proteins were 
identified by mass spectrometry as 
ceruloplasmin (CERU), fibrinogen (FGN) and 
albumin (HSA). Immunodot blot analysis of 
SEC fractionated plasma suggested that CLU-
client complexes generated in situ are very 
large and may reach ≥ 4 x 107 Da. Lastly, 
sandwich ELISA detected complexes 
containing CLU and CERU, FGN or HSA in 
stressed but not control plasma. We have 
previously proposed that CLU-client 
complexes serve as vehicles to dispose of 
damaged misfolded extracellular proteins in 
vivo via receptor-mediated endocytosis. A 
better understanding of these mechanisms is 
likely to ultimately lead to the identification of 
new therapies for extracellular protein 
deposition disorders. 
 
Processes to attain and maintain native 
protein conformations are vital for organismal 
viability. Conditions such as thermal and 
oxidative stress may cause proteins to partially 
unfold and aggregate - a process thought to 
underpin the pathology of many so-called protein 
deposition diseases, including Alzheimer’s 
disease, arthritis, type II diabetes, age-related 
macular degeneration (ARMD) and 
atherosclerosis (1-5). While intracellular 
mechanisms to monitor and control the folding 
state of proteins are well characterized, 
corresponding extracellular mechanisms have yet 
to be established. It has been proposed that 
clusterin (CLU) is one of a small family of 
abundant extracellular chaperones that form part 
of a quality control system which acts to stabilize 
misfolded, aggregating extracellular proteins and 
mediate their clearance from the body via 
receptor-mediated endocytosis and lysosomal 
degradation (6-8).  
CLU can stabilize proteins and prevent 
their precipitation during exposure to a variety of 
stresses in vitro (9-14). This action involves the 
formation of soluble high molecular weight 
(HMW) complexes incorporating both CLU and 
the stressed client protein at an approximate mass 
ratio of 1:2 (CLU:client); when generated in 
vitro, these complexes have diameters of 50 - 100 
nm (14). CLU is found associated with 
extracellular protein deposits in many serious 
diseases including drusen in ARMD (15), renal 
immunoglobulin deposits in kidney disease (16), 
prion deposits in Creutzfeldt-Jakob disease (17), 
amyloid plaques in Alzheimer’s disease (18,19) 
and also in atherosclerotic plaques (20). The 
presence of CLU in these pathological deposits 
suggests that it associates with unfolding proteins 
in vivo. Pathological protein deposition may thus 
result when the chaperone capacity of CLU and 
other machinery acting to prevent the 
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accumulation of protein aggregates is exceeded 
by abnormally high levels of protein unfolding.  
In addition to misfolded client proteins, 
CLU also binds to many native ligands; the nature 
of these latter interactions remain largely 
uncharacterized, however, it is believed that CLU 
has discrete binding sites for native ligands and 
misfolded client proteins (12,21). Typically, 
investigations of the chaperone activity of CLU 
have been carried out using model proteins that 
can be induced to unfold at experimentally 
convenient rates. It was previously shown that 
depletion of CLU from human plasma increased 
the extent of plasma protein precipitation at both 
60°C (11) and 37°C (22). However, the identity of 
the major chaperone client proteins for CLU in 
human plasma was previously unknown. The 
identity of these client proteins may provide 
important insights into mechanisms underlying 
the development of extracellular protein 
deposition diseases. In this study we exposed 
human plasma to physiologically-relevant stress 
(gentle rotation to produce shear stress ~36 
dye/cm2 at 37°C for 10 days) and used 
electrophoresis, Western blotting, and mass 
spectrometry to identify proteins that co-purified 
with CLU from stressed (but not control) plasma 
by immunoaffinity chromatography. Immunodot 
blot assays of fractions from size exclusion 
chromatography (SEC), and sandwich ELISA, 
were used to confirm that these putative 
endogenous plasma client proteins formed soluble 
HMW complexes with CLU in stressed human 
plasma 
 
EXPERIMENTAL PROCEDURES 
 
Materials - All buffer salts were obtained 
from Ajax Chemical Co. Ortho-
phenylenediamine, 2-β-mercaptoethanol, BCA 
reagent, goat anti-FGN antiserum, goat anti-
CERU antiserum, rabbit anti-HSA antiserum, 
control goat serum, control rabbit serum and 
mouse anti-goat Ig-HRP were from Sigma-
Aldrich. Sheep anti-rabbit Ig-HRP and control 
mouse IgG1 were obtained from Millipore. 
Purified mouse monoclonal anti-CLU IgG1 (G7) 
was as described in (23).   
Isolation of Plasma Proteins Co-
Purifying with CLU - Whole blood supplemented 
with 20 µM sodium citrate was centrifuged at 
1,020 x g for 30 min to pellet cells. The plasma 
was collected and supplemented with CompleteTM 
Protease Inhibitor Cocktail (Roche) and 0.1% 
(w/v) sodium azide (Az). One 50 mL aliquot was 
immediately filtered through a GF/C microfibre 
glass filter (Whatman) and passed at 0.5 mL/min 
over monoclonal anti-CLU immunoaffinity 
columns (with an approximate total bed volume 
of 20 mL), as previously described (25). The 
columns were subsequently washed with several 
column volumes of phosphate buffered saline 
(PBS; 137 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, 8 mM Na2HPO4, pH 7.4) containing 
0.1% (w/v) Az (i.e. PBS/Az) before the bound 
protein was eluted using 2 M GdHCl in PBS, pH 
7.4. A second 50 mL aliquot of plasma (from the 
same batch) was "stressed" as follows: plasma 
was held in a 100 mL Schott bottle in a Bioline 
472 incubator shaker (Edwards Instrument Co.) 
rotating at 200 rpm at 37°C for 10 days. This is 
estimated to correspond to an approximate shear 
stress of 36 dye/cm2 (24). Subsequently, this 
sample was processed as above using the same 
immunoaffinity procedure.  In some cases, where 
it was not possible to use freshly isolated plasma 
as the control (i.e. in sandwich ELISA and 
measurements of turbidity where absorbance 
readings were required to be obtained 
concurrently), control plasma (from the same 
batch) was left static at room temperature for 10 
days.  
Plasma Protein Precipitation Assays - 
Total plasma protein precipitation was assessed 
by microprotein assay and by spectrophotometry. 
For each plasma sample (control or stressed), 
three 200 µL aliquots of plasma were filtered 
using separate 0.45 µm Ultrafree®-MC 
centrifugal filter devices (Millipore). The 
precipitate collected on the membranes was 
extensively washed with PBS. The membranes 
were then covered with 200 µL of 6 M GdHCL in 
PBS and incubated at 60°C with shaking 
overnight. Parafilm “M” (Pechiney Plastic 
Packaging) was used to seal the membrane cups 
and ensure that no liquid volume was lost during 
heating. The solutions were diluted 1:50 in PBS 
before a BCA assay was performed (Smith et al., 
1985). In addition, control or stressed plasma was 
diluted 1:2 in PBS/Az in a quartz cuvette and the 
A360 nm measured using a WPA Biowave S2100 
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Diode Array Spectrophotometer (Biochrom). 
Statistical significance was determined using one-
way analysis of variance (ANOVA) and Tukey 
HSD. 
Size Exclusion Chromatography (SEC) - 
SEC of 500 µL whole plasma or anti-CLU 
immunoaffinity eluate was carried out using a 
SuperoseTM 6 10/300 column (GE Healthcare) 
equilibrated in PBS/Az at the recommended flow 
rate of between 0.3-0.5 mL/min and the 
absorbance at 280 nm (A280 nm) continuously 
monitored using an ÄKTA FPLC system (GE 
Healthcare). Mass standards were from a 
commercial HMW calibration kit (GE 
Healthcare). All buffers and samples were filtered 
(0.45 µm) before use. For immunodot blot 
analysis of whole plasma, 0.5 mL fractions were 
collected. 
 SDS-PAGE and Identification of Proteins 
by Mass Spectrometry - Proteins purified by anti-
CLU immunoaffinity chromatography from 
plasma samples (40 mg total protein per lane) 
were separated on 8-15% SDS-PAGE gels using 
a HoeferTM SE 250/260 SDS-PAGE system (GE 
Healthcare). Mass spectrometry was outsourced 
commercially and performed by the Australian 
Proteome Analysis Facility (APAF). Selected 
Coomassie Blue stained bands were excised from 
gels using a scalpel blade. Excised bands were 
treated in-gel with PNGaseF followed by tryptic 
digestion for 16 h. MALDI mass spectrometry 
was performed with an Applied Biosystems 4800 
Proteomics Analyzer. The spectra were acquired 
in reflectron mode in the mass range 700 to 3500 
Da. The instrument was then switched to MS/MS 
(TOF/TOF) mode where peptides from the MS 
scan were isolated and fragmented, then re-
accelerated to measure their masses and 
intensities. Spectra were then examined using the 
database search program Mascot (Matrix Science 
Ltd). High Mowse scores (> 69) in the peptide 
database search indicated a likely match  
(p < 0.05).  
 Western Blot and Immunodot Blot  
Analyses - For Western blots, following SDS-
PAGE performed as described above (loading 10 
µg total protein into each lane), gels were 
subsequently equilibrated in transfer buffer  
(26 mM TRIS, 192 mM glycine, 20% (v/v) 
methanol, pH 8.3) and separated proteins 
transferred to nitrocellulose membrane using a 
Mini Trans-Blot Cell Western blotting apparatus 
(Bio-Rad) at 100 V for 1 h at 4°C. The membrane 
was subsequently blocked overnight at 4oC in 1% 
(w/v) heat denatured casein (HDC) in PBS 
(HDC/PBS). Primary and appropriate HRP-
conjugated secondary antibodies, diluted in 
HDC/PBS following the manufacturer's 
instructions, were incubated in turn with the 
membrane for 1 h at 37 °C. The membrane was 
then washed in 0.1% (v/v) Triton X-100 in PBS 
followed by PBS alone. Enhanced 
chemiluminescence detection was performed 
using Supersignal Western Pico substrate (Pierce 
Biotechnology, Rockford, USA) following  
the manufacturer’s protocols. Amersham 
HyperfilmTM ECL (GE Healthcare) was placed 
over the membrane in a Kodak X-Omatic cassette 
to detect chemiluminescence. Once exposed, the 
film was removed from the cassette and 
developed using Kodak Developer and Fixer. 
Densitometry was performed using a GS 800 
calibrated densitometer (Bio-Rad) and Quantity 
One software (Bio-Rad). The average optical 
density/mm2 of the bands was used to estimate 
their relative quantities. 
For immunodot blots, plasma (control or 
stressed) was fractionated over a SuperoseTM 6 
10/300 column as described above. Four 
microliters of each 0.5 mL fraction was spotted 
onto nitrocellulose membrane and allowed to dry 
before a second 4 µL aliquot was applied. The 
dried membranes were then blocked and 
processed as described above for Western blot. 
Sandwich ELISA - The wells of an 
ELISA plate (Greiner Bio-one) were coated with 
10 mg/mL purified G7 anti-CLU antibody (23) or 
control mouse IgG1 antibody, then blocked with 
1% (w/v) BSA in PBS (BSA/PBS) or HDC/PBS. 
Control plasma (left static at room temperature) 
or stressed plasma was next added to the wells. 
Subsequently, primary antisera reactive with 
either CERU, FGN or HSA diluted in the 
blocking solution (following the manufacturer’s 
instructions) were added to the appropriate wells. 
Finally, an appropriate horseradish peroxidase 
(HRP) conjugated secondary antibody diluted in 
blocking solution (following the manufacturer’s 
instructions) was added. All incubations were for 
1 h at 37 ºC with shaking, and extensive washing 
with PBS was performed between each step. The 
final wash was performed using 0.1% (v/v) 
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Triton-X 100 in PBS followed by PBS alone. 
Ortho-phenylenediamine (2.5 mg/ml) and 0.03 % 
(v/v) H2O2 in 50 mM citric acid, 100 mM 
Na2HPO4, pH 5 was then added to the wells of 
the plate. The reaction was stopped using 1 M 
HCL before the A490 nm was measured using a 
SpectraMax Plus384 microplate reader (Molecular 
Devices). Non-specific binding was assessed 
using species–matched anti-sera of irrelevant 
specificity and the appropriate secondary 
antibody. The results presented are adjusted for 
non-specific binding by calculating the 
absorbance in wells coated with G7 relative to the 
absorbance in wells coated with control mouse 
IgG1 (of irrelevant specificity) that were treated 
with the same plasma, primary and secondary 
antibodies. Statistical significance was 
determined using Student’s t-test. 
 
RESULTS 
 
Stress-induced protein precipitation. 
After 10 days, compared to control plasma held at 
room temperature, stressed plasma was visibly 
more turbid. The turbidity of control plasma 
remained unchanged over this period, however 
after 10 days the turbidity of stressed plasma was 
significantly greater than at day 0 and that of 
control plasma at either time point (Fig. 1;  
F (3,8) = 433, Tukey HSD, p < 0.0001 in all 
cases). When performed as described, the 
bicinchoninic (BCA) assay was unable to detect 
protein in the filtrates of freshly obtained control 
plasma but detected a mean ±  standard error  
(n = 3) of 8.47 ± 0.99 mg protein in the 
corresponding filtrates from 200 µL aliquots of 
stressed plasma.  
Bias towards HMW species as detected by 
SEC of stressed plasma and anti-CLU co-
purifying proteins. There were differences in the 
SEC profiles of freshly isolated control and 
stressed plasma samples (Fig. 2A). Most notably, 
the respective areas underneath the traces of 
absorbance at 280 nm (A280 nm) suggest that 
there was less soluble protein in stressed plasma 
compared to an equal volume of control plasma. 
Although there appeared to be less soluble protein 
in the stressed sample, the amount of protein 
eluting at the exclusion limit of the column  
(4 x 107 Da) was similar for both plasma samples 
(Fig. 2A), indicating that overall a greater 
proportion of stressed plasma proteins migrated as 
very large species. SEC profiles of proteins 
purified by anti-CLU immunoaffinity 
chromatography from freshly isolated control 
versus stressed plasma were very different  
(Fig. 2B). The A280 peak eluting at the column 
exclusion limit was approximately four times 
greater for proteins immunoaffinity purified from 
stressed plasma versus control plasma. Moreover, 
the majority of species in the former sample were 
larger than about 600 kDa whereas those in the 
latter sample were predominately smaller in mass 
(Fig. 2B). 
Identification of major plasma clients for 
clusterin. When equivalent amounts of total 
protein purified by anti-CLU immunoaffinity 
chromatography from control and stressed plasma 
were analyzed side-by-side by reducing SDS-
PAGE, many bands were detected in both 
samples (Fig. 3). A major band at about 36 kDa, 
corresponding to the co-migrating α and β 
subunits of CLU, was detected in both samples, 
however, this was considerably more prominent 
in the control sample (Fig. 3). In the sample 
prepared from control plasma, other protein bands 
detected probably include those representing 
ApoA-I (~ 28 kDa) and IgG (light chain ~ 23 kDa 
and heavy chain ~ 50 kDa), which are known to 
co-purify with CLU from normal human plasma 
(23,25), as well as other minor contaminants 
which can be removed from CLU by subsequent 
ion exchange chromatography (26). Additional 
bands that were unique or more prominent in the 
sample prepared from stressed plasma were also 
detected (Fig. 3). Several of these bands 
(indicated by empty arrowheads on Fig. 3) were 
excised and subjected to mass spectrometry 
analysis (multiple gels of various percentage 
acrylamide were used to adequately resolve bands 
for mass spectrometry, however a single 
representative gel is shown). These analyses 
identified ceruloplasmin (CERU), fibrinogen 
(FGN; β chain) and human serum albumin (HSA) 
as putative chaperone client proteins for CLU 
(Table 1).  
Western blot analysis was used to confirm 
that CERU, FGN and HSA co-purified with CLU 
from stressed plasma but not (or to a lesser extent) 
from control plasma (Fig. 4). At most, only traces 
of CERU and FGN were detected in the 
corresponding protein fractions purified in the 
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same way from control plasma (Fig. 4A and B). 
There was measurable HSA in the fraction 
prepared from control plasma, however, this was 
reproducibly substantially less than in the sample 
prepared from stressed plasma (Fig. 4C). A band 
representing HSA was detected at about the 
position expected for the intact molecule (69 kDa, 
panel C), but the same was not true for CERU. 
Intact CERU has a mass of 122 kDa, however it is 
prone to autolysis in plasma to yield fragments of 
67, 53 and 20 kDa (27) which corresponded to the 
approximate position of the major bands detected 
on the blot (Fig. 4A). Bands corresponding to the 
α, β and γ chains of FGN (25 kDa, 56 kDa and 48 
kDa, respectively) were detected in the lane 
containing proteins from stressed plasma. In 
plasma, FGN is highly susceptible to proteolysis 
and is present in many fragmented and cross-
linked forms (28,29). Therefore, FGN bands 
detected between about 29-36 kDa are likely to 
represent β and γ chain degradation products (Fig. 
4B). 
CLU forms HMW complexes with 
chaperone client proteins in vitro (9,10,12,14). If 
CLU-client protein complexes formed in situ in 
plasma are also large, then relative to unstressed 
control plasma, a greater proportion of CLU and 
the client proteins would be detected as HMW 
species in stressed plasma. This was examined 
using SEC to fractionate both control and stressed 
plasma on the basis of molecular size, and then 
probing the fractions with specific antibodies. Fig. 
5 shows immunodot blot results for SEC fractions 
representing species corresponding to between 
460 kDa and the exclusion limit of the column (≥ 
4 x 107 Da) in mass probed with specific 
antibodies for CLU, CERU, FGN and HSA. 
Strikingly, CLU and all three client proteins were 
detected much more strongly in the HMW 
fractions (≥ 4 x 107 Da) prepared from stressed 
plasma compared to the corresponding fractions 
of control plasma (Fig. 5). Most of the 
corresponding fractions from control plasma 
showed little reactivity with antibodies specific 
for CLU, CERU, FGN and HSA. This is 
consistent with the known mass of these 
individual proteins (CLU 61 kDa, CERU 122 
kDa, FGN 340 kDa and HSA 69 kDa) - the bulk 
of these proteins would elute in later fractions not 
represented in this figure unless they were present 
as aggregates or complexes. The limited reactivity 
detected for the client proteins in the control 
plasma lanes probably represents low-level 
associations of these proteins with other 
unidentified plasma components or self-
association (see Discussion). 
The results thus far indicated a 
preferential association of CERU, FGN and HSA 
with CLU in stressed human plasma. If this 
association was the result of the chaperone action 
of CLU, then it would be expected that complexes 
incorporating both CLU and one or more of these 
three putative client proteins would be present in 
stressed plasma but not in control plasma. This 
was verified by sandwich ELISA. The wells of an 
ELISA plate were coated with an anti-CLU 
antibody (or an isotype-matched control antibody) 
and subsequently incubated with control or 
stressed plasma. Bound CERU, FGN or HSA 
were then detected with specific antibodies. In 
this assay, absorbance at 490 nm significantly 
above that of the controls will only occur if 
species containing both CLU and a putative client 
protein are specifically bound to the anti-CLU 
antibody on the wells. For all three putative client 
proteins tested, significantly greater absorbance 
was measured in wells incubated with stressed 
plasma compared to those incubated with control 
plasma (Fig. 6; CERU, FN and HSA t(4) = 9.06, 
t(4) = 4.85, t(4) = 4.99, respectively; p ≤ 0.02 in 
all cases). When irrelevant control antibodies 
matched by isotype and species to the primary 
detection antibody were used in the same assay, 
there was no significant difference between wells 
incubated with stressed or control plasma (control 
antisera results, Fig. 6).  
 
DISCUSSION 
 
 Exposure to physical and chemical 
stresses, such as elevated temperature, shear 
stress, oxidative stress and UV irradiation, 
challenge all biological systems. One potential 
impact of these stresses is damage to proteins, 
inducing misfolding, loss of function and 
aggregation. While much is known about 
intracellular mechanisms that act to repair or 
dispose of stress-damaged proteins, little is known 
about corresponding extracellular mechanisms. 
When comparing the intracellular and 
extracellular environments, some stresses that can 
contribute to protein unfolding are greater in the 
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latter. This includes hydrodynamic shear stress 
resulting from the hydraulic force of plasma being 
pumped around the body (30,31); normal arterial 
shear stress is between 10-70 dye/cm2 (32). The 
extracellular environment is also more oxidizing 
than the cytosol (33). In this study, we used a 
constant temperature of 37°C and an estimated 
shear stress (generated by orbital shaking) of 
around 36 dye/cm2 (calculated using the formula 
of (24)) to simulate physiologically-relevant 
extracellular conditions.  Relative to plasma left 
stationary at room temperature, plasma stressed in 
this way for 10 days showed increased turbidity 
and protein precipitation (Fig. 1). This result 
indicates that plasma proteins are prone to 
unfolding and aggregation under conditions of 
temperature and shear stress that are likely to 
occur in vivo. If this is the case, then intuitively, 
the human body must have systems in place to 
control this problem. 
SEC indicated that the level of soluble 
protein remaining in stressed plasma was less 
than in batch-matched control plasma, and that 
proportionately more proteins were present as 
HMW species in stressed plasma (Fig. 2). These 
findings may be explained by the stress-induced 
partial unfolding of plasma proteins, which 
subsequently aggregate to form increasingly large 
aggregates, some of which eventually become too 
large to stay in solution and form insoluble 
precipitate. Superimposed on this process, we 
suggest that under these conditions CLU forms 
large soluble complexes with probably many 
different misfolded plasma client proteins. This 
has the effect of ameliorating the extent of protein 
precipitation measured. We have previously 
shown that the immunoaffinity depletion of CLU 
from human plasma significantly increased total 
protein precipitation in this fluid when it was 
subsequently incubated at either 60oC (11) or 
37oC (22). Species ≥ 4 x 107 Da in stressed 
plasma may be aggregates on their way towards 
becoming insoluble or may be aggregates 
stabilized by extracellular chaperones such as 
CLU. CLU is itself physically very stable and 
does not aggregate or precipitate even in response 
to sustained heating at 60°C (9,12-14). Thus, the 
apparent depletion of CLU from the pool of 
soluble proteins in stressed plasma in the current 
study (Fig. 3) probably results from its 
incorporation into growing aggregates; under the 
conditions tested, CLU is unable to maintain the 
solubility of all plasma proteins. Supporting the 
involvement of CLU in forming HMW 
chaperone-client complexes, SEC of proteins 
purified by anti-CLU immunoaffinity 
chromatography from stressed and control plasma 
indicated that, relative to the latter, the former 
was dominated by HMW protein species. If it had 
been possible to elute proteins from the anti-CLU 
columns using non-denaturing conditions (instead 
of the 2M GdHCl used in this study), the 
difference in mass profile for the two samples 
might have been even greater. Our recent work 
showed that when CLU-client protein complexes 
were generated from purified proteins in vitro, the 
mass ratio was, for each of three different client 
proteins, approximately 1:2, respectively (14). 
The complexes in the current study were purified 
from stressed human plasma by immunoaffinity 
chromatography, which (unavoidably) involved 
eluting bound complexes with denaturing 
conditions. The harsh elution conditions are likely 
to have led to partial disruption of the complexes, 
thus making measurements of stoichiometry 
rather meaningless. For this reason we did not 
measure the apparent stoichiometry of the 
complexes in the current study.  
SDS-PAGE analyses of proteins bound 
from control plasma to anti-CLU columns were 
consistent with our experience in routine 
purifications of plasma CLU (26). The protein 
bands detected (additional to CLU) are likely to 
represent known CLU ligands such as 
complement components (34), IgG (23) and Apo-
A1 (25). However, other bands were detected as 
uniquely present (or more abundant) in samples 
prepared from stressed plasma - these bands were 
regarded as corresponding to putative endogenous 
plasma client proteins for the chaperone action of 
CLU. In this study, three bands were selected 
from one-dimensional SDS-PAGE for further 
analysis. It is expected that in the future, by 
applying a protein separation technique with 
greater resolution such as two-dimensional SDS-
PAGE, further putative client proteins will be 
identified. Previous studies indicate that the 
chaperone action of CLU is promiscuous (6,9-
14,35), thus it is likely that CLU will interact with 
most misfolding proteins, regardless of their 
identity and that endogenous CLU-client 
complexes will contain a heterogeneous mix of 
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client proteins. However, using the approaches 
described, identification of specific plasma 
proteins as clients for CLU will depend on their 
individual relative abundances and stabilities. In 
the current study, mass spectrometric analysis of 
the three bands resolved by one-dimensional 
SDS-PAGE identified them as corresponding to 
CERU, FGN and HSA (Fig. 3 and Table I). 
Western blot analyses showed that these three 
putative client proteins were preferentially 
detected in protein fractions prepared by anti-
CLU immunoaffinity chromatography of stressed 
plasma versus control plasma (Fig. 4). The small 
amounts of the putative client proteins co-
purifying with CLU from control plasma (Fig. 4, 
control (C) lanes) may be the result of low levels 
of CLU-client complexes present in freshly 
isolated plasma. However, low-level non-specific 
binding of client proteins to the anti-CLU 
immunoaffinity columns may also contribute in 
this regard, particularly in the case of HAS, which 
is known to bind to many surfaces.  
Species much larger than expected for 
monomeric CLU, CERU, FGN and HSA were 
detected by immunodot blot analysis of SEC 
fractionated samples of both control and stressed 
plasma. CLU is well known to oligomerize in 
solution to form a variety of HMW aggregates 
(9,14) and also to associate with HDL particles in 
plasma (25); this would account for the large  
(460 kDa to > 737 kDa) CLU-containing species 
detected in control plasma (Fig. 5A). In the case 
of CERU, FGN and HSA, the large (>460 kDa) 
species containing these proteins detected in 
control plasma probably result from interactions 
between them and other plasma proteins. Many 
examples of such interactions are known, for 
example lactoferrin (36), protein C (37), 
myeloperoxidase (38) interact with CERU; at 
least 11 proteins are known to interact with FGN  
including vitronectin (39), histidine-rich 
glycoprotein (40) and apolipoprotein(a) (41); and 
over 60 different proteins are believed to interact 
with HSA (42). Also, self aggregation which has 
been reported for both FGN (43) and HSA (44). 
Corresponding analyses of stressed plasma 
strongly detected CLU and each of the three client 
proteins CERU, FGN and HSA in fractions 
representing still larger species approaching (or 
at) the exclusion limit of the SEC column (4 x 107 
Da; Fig. 5). This observation is consistent with 
CLU forming large HMW complexes with client 
proteins in stressed plasma, as has been described 
for purified proteins in buffered solutions 
(9,10,12,14). Finally, using sandwich ELISA, we 
were able to confirm that CLU-CERU, CLU-FGN 
and CLU-HSA complexes were present in 
stressed but not control plasma (Fig. 6). 
Collectively, these results indicate that under 
conditions of mild, physiologically-relevant 
stress, CLU forms soluble chaperone-client 
complexes in plasma containing one or more of 
CERU, FGN and HSA.  
The observation that CLU is found 
associated with insoluble protein aggregates in all 
protein deposition diseases in which this has been 
examined (45) suggests that CLU (i) binds to 
unfolding proteins in vivo, and (ii) becomes 
incorporated into protein deposits when its 
chaperone action is overwhelmed by an excess of 
misfolded protein. All three CLU client proteins 
identified in this study are involved in protein 
deposition diseases. CERU, FGN and HSA are 
found in ARMD deposits known as drusen 
(15,46-49). Additionally, plasma concentrations 
of CERU and FGN are higher in ARMD 
compared to normal patients (50,51).  Co-
localization of CLU with drusen proteins is very 
common in ARMD (15), furthermore, in this 
same disease, non-drusen FGN deposition is 
implicated in the atrophy of the retinal pigment 
epithelium and choroidal neovascularization 
(52,53). The progression of both atrophic and 
neovascular ARMD is supported by platelet 
activation which results in secretion of growth 
factors and monocyte chemoattractants. Platelet 
activation is enhanced by unfolding of FGN (54) 
and results in the release of CLU from the 
platelets by degranulation (55).  The effects of the 
interaction between CLU and stressed FGN on 
platelet activation are currently unknown - this 
may have significance not only to ARMD, but 
also to the many ischemic and atherosclerotic 
vascular conditions where FGN deposition is 
known to occur (5,56-58). As in ARMD, 
fibrinogen deposition in such diseases is 
associated with the recruitment and activation of 
platelets and has been proposed as a mechanism 
for vascular injury (59). Deposition of fibrinogen 
(FGN) has been reported in breast cancer (60), 
mesothelioma (61), colon cancer (62) and 
lymphoma (63). Although the reasons for this are 
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unknown, one potential implication of this 
observation is that FGN deposition promotes 
angiogenesis and cancer progression. FGN 
deposits are also found in renal disease (64,65), 
hereditary renal amyloidosis (66) and systemic 
lupus erythematosus (67). In Type 1 (insulin-
dependent) diabetes mellitus, extracellular 
deposition of HSA is observed around dermal 
capillaries (68), kidney (69,70), skeletal muscle 
(71) and the thyroid gland (72).  
Given the large number of diseases in 
which extracellular protein deposition occurs (1-
5,8), characterization of mechanisms that clear 
damaged proteins in healthy individuals is likely 
to shed light on how protein deposition 
pathologies arise. In this study we have identified 
three plasma client proteins that bind to CLU 
during physiologically relevant stress. Their 
deposition in numerous conditions suggests that 
overwhelming or disruption of normal activities 
that prevent their accumulation in healthy 
individuals is important in the progression of 
disease. The in vivo interaction of CLU with these 
client proteins (and others) in vivo is likely to be 
an important mechanism to prevent the 
pathological deposition of misfolded extracellular 
proteins. Significantly, it has been shown that 
CLU knock-out mice develop progressive 
glomerulopathy which is characterized by the 
accumulation of insoluble protein deposits in the 
kidneys (73). This directly implicates CLU in the 
clearance of potentially pathological aggregating 
proteins, although the precise mechanism 
underlying this has yet to be described. It has 
been proposed to occur via the receptor-mediated 
endocytosis and subsequent lysosomal 
degradation of extracellular chaperone-client 
protein complexes (6). Evidence is rapidly 
accumulating that CLU and other abundant 
extracellular chaperones are key elements in a 
quality control system for extracellular protein 
folding (6-14,21,22,35,45,74-79). This report is 
an important step towards a fuller understanding 
of the vital mechanisms involved in extracellular 
protein folding quality control. 
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The abbreviations used are: A280 nm, absorbance at 280 nm; A490 nm, absorbance at 490 nm; ARMD, 
age-related macular degeneration; Az, sodium azide; BSA, bovine serum albumin; CERU, ceruloplasmin; 
CLU, clusterin; FGN, fibrinogen; G7, monoclonal anti-CLU IgG1; HDC, heat denatured casein; HMW, 
high molecular weight; HSA, human serum albumin; PBS, phosphate buffered saline; SEC, size exclusion 
chromatography. 
 
TABLE LEGENDS 
 Table 1. Identification of proteins by mass spectrometry. Proteins co-purifying with CLU from stressed 
plasma (indicated by open arrows in Fig. 3) were analyzed by MALDI TOF/TOF. Spectra were examined 
using the database search program Mascot (Matrix Science Ltd, London, UK). Mowse scores (> 69) in the 
peptide database search indicated a likely match (p < 0.05). 
 
   
FIGURE LEGENDS 
Fig. 1. Turbidity of control and stressed plasma at day 0 and day 10. Plasma samples were diluted 1:2 in PBS on day 
0 and day 10 and the A360 nm measured. The figure shows the average A360 nm (n = 3 ± standard error) for each 
sample.  * Denotes significantly increased turbidity relative to the three other sample types (Tukey HSD, p < 0.0001 
in all cases). These results are representative of 3 independent experiments. 
 
 
Fig. 2. SEC of (A) stressed or control plasma and (B) anti-CLU immunoaffinity purified proteins from stressed or 
control plasma. Samples analyzed were: (A) whole plasma exposed to shear stress for 10 days or freshly isolated 
control plasma, and (B) proteins purified by anti-CLU immunoaffinity chromatography from the plasma samples 
described in (A). The positions of molecular weight markers are indicated by labelled arrows; the exclusion limit (Vo) 
≥ 4 x 107 Da. The results shown are representative of 2 independent experiments. 
 
 
Fig. 3. SDS-PAGE of proteins purified from stressed or control human plasma by anti-CLU immunoaffinity 
chromatography. Proteins were separated using 12% SDS-PAGE under reducing conditions. The figure shows 
molecular weight markers (left lane, masses indicated in kDa), and proteins immunoaffinity purified from freshly 
isolated control plasma (labelled C) or stressed plasma (labelled S). Open arrows indicate bands that were selected 
for mass spectrometry analysis. The solid black arrow indicates the position of CLU. The results shown are 
representative of many independent experiments. 
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Fig. 4. Western Blot analysis of proteins purified by anti-CLU immunoaffinity chromatography from control or 
stressed human plasma. Proteins separated by SDS-PAGE (10 µg total protein loaded per lane) were transferred to 
nitrocellulose membrane and probed with (A) anti-CERU, (B) anti-FGN or (C) anti-HSA antisera. Each panel shows 
the position of molecular weight markers (left lanes, masses in kDa indicated), and proteins immunoaffinity purified 
from freshly isolated control plasma (labelled C) or stressed plasma (labelled S). In (B), the position of the α, β and γ 
subunits of FGN are indicated. The results shown are representative of 3 independent experiments. 
 
 
Fig. 5.  Immunodot blot analyses of SEC-fractionated control or stressed human plasma. Freshly isolated control 
plasma (C) or stressed plasma (S) were fractionated using a SuperoseTM 6 column (V0 ≥ 4 x 107 Da). Aliquots from 
each fraction were spotted onto nitrocellulose membrane which was then incubated with antibodies against (A) CLU, 
(B) CERU, (C) FGN, or (D) HSA followed by the appropriate HRP-conjugated secondary antibody prior to 
development by ECL. The approximate molecular weight of the SEC fractions is indicated at the top of the figure. 
The results shown are representative of 3 independent experiment. 
 
Fig. 6. Detection of CLU-client protein complexes in stressed plasma by sandwich ELISA. Results of sandwich 
ELISA detecting CLU-client protein complexes containing (A) CERU, (B) FGN or (C) HSA in human plasma. 
Results for "control antisera" were obtained using species-matched control antisera as the primary detection antibody 
in each case. The results shown are the average A490 (n = 3, ± standard error) relative to the non-specific binding 
generated in wells coated with mouse IgG1 control antibody. * Denotes increased A490 relative to wells incubated 
with control plasma (stored static at 4°C; Student’s t-test, p ≤ 0.02). The results shown are representative of 3 
independent experiments 
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Table 1 
 
BAND MASS IDENTITY MOWSE 
SCORE 
COVERAGE SIGNIFICANCE 
 
1 
 
 
17 kDa 
 
CERU 
 
175 
 
35% 
 
p < 0.05 
 
2 
 
 
43 kDa 
 
FGN 
(β chain) 
 
157 
 
54% 
 
p < 0.05 
 
3 
 
 
67 kDa 
 
HSA 
and 
CERU 
 
398 
 
97 
 
54% 
 
34% 
 
p < 0.05 
 
p < 0.05 
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